Compare Moderna, Inc. (MRNA) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Northrop Grumman Corporation — how do they compare? Moderna, Inc. trades at $62.25 (market cap $24.18B), while Northrop Grumman Corporation trades at $573.1 (market cap $81.78B). The key difference: Northrop Grumman Corporation is far larger — about 3.4× Moderna, Inc.'s market cap, and Northrop Grumman Corporation pays a 1.63% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | NOC | |
|---|---|---|
Market Cap | $24.18B | $81.78B |
Sector | Health | Industrials |
52-Week High | $81.80 | $768.02 |
52-Week Low | $22.36 | $496.02 |
Enterprise Value | $20.33B | $95.77B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Northrop Grumman (NOC) trades at $577.89, up 1.1% today, with a bullish technical signal from moving averages and a record $105 billion backlog supporting fundamentals. Recent Q2 2026 earnings beat expectations, with sales growth of 5% and raised full-year guidance (Seeking Alpha, 2026-07-23). Valuation ratios like P/E of 18.3 and ROE of 26.96% reflect strong profitability, though RSI levels indicate overbought conditions.
The outlook is positive due to defense spending tailwinds and strategic contracts, but risks include margin pressure from specific programs and geopolitical volatility. Analysts maintain a buy consensus with a $598.57 price target, suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
